Neoadjuvant combination immunotherapy may improve survival compared with single-agent therapy for patients with head and neck squamous cell carcinoma, according to results of a randomized phase 2 ...

The combination therapy can be used as first-line treatment for unresectable or metastatic forms of the cancer.

Esophageal cancer is a rare cancer ... Examples include pembrolizumab (Keytruda), nivolumab (Opdivo), and ipilimumab (Yervoy). Because these intravenous drugs affect the immune system, they ...

The combination of nivolumab with ipilimumab was approved for unresectable or metastatic microsatellite instability-high (MSI ...

During a live event, Matthew Galsky, MD, discussed adjuvant nivolumab in muscle-invasive bladder cancer and the benefit in ...

The Harrison resident, diagnosed with esophageal cancer in 2021, worried about looking his best for his son’s wedding. “I was all worked up,” said Hines, 60, retired after 30 years with the ...

Progression-free survival was significantly greater in the nivolumab plus ipilimumab group compared to nivolumab alone. 2. Treatment-related adverse events were slightly higher in nivolumab plus ...

Opdivo and Opdivo-based combinations have also shown improved efficacy in the neoadjuvant or adjuvant treatment of four tumor types — lung cancer, bladder cancer, esophageal/gastroesophageal ...

Neoadjuvant nivolumab has demonstrated efficacy in patients with mismatch repair-deficient (dMMR), surgically resectable endometrial cancer, according to findings presented at the SGO 2025 Annual ...

A total of 495 patients were randomized to receive either “subcutaneous nivolumab ... lung cancer; head and neck squamous cell carcinoma; colorectal cancer, hepatocellular carcinoma, esophageal ...

PRINCETON, N.J., March 28, 2025--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency ...